Septerna, Inc. Stock-Based Compensation
Septerna, Inc. (SEPN) reported Stock-Based Compensation of $5.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- Septerna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.07M, a 180.95% increase year-over-year.
- Septerna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.01M, a 305.87% increase year-over-year.
- Septerna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.66M, a 110.13% increase year-over-year.
- Septerna, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.53M, a 270.72% increase year-over-year.
- Septerna, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $8.48M, a 168.91% increase from fiscal 2024.
- Septerna, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.15M, a 94.57% increase from fiscal 2023.
- Septerna, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.62M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.07M 10-Q · filed 2026-08-10 | $11.09M 10-Q · filed 2026-08-10 | $13.74M derived: sum of 3 quarters · filed 2026-08-10 | $16.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $6.01M 10-Q · filed 2026-05-11 | $8.67M derived: sum of 2 quarters · filed 2026-05-11 | $11.20M derived: sum of 3 quarters · filed 2026-05-11 | $13.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.19M derived: sum of 2 quarters · filed 2026-03-09 | $6.99M derived: sum of 3 quarters · filed 2026-08-10 | $8.48M 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.53M 10-Q · filed 2025-11-10 | $4.34M derived: sum of 2 quarters · filed 2026-08-10 | $5.82M 10-Q · filed 2025-11-10 | $7.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.81M 10-Q · filed 2026-08-10 | $3.29M 10-Q · filed 2026-08-10 | $4.55M derived: sum of 3 quarters · filed 2026-08-10 | $5.24M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-11 | $2.75M derived: sum of 2 quarters · filed 2026-05-11 | $3.43M derived: sum of 3 quarters · filed 2026-05-11 | $4.06M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.95M derived: sum of 2 quarters · filed 2026-03-09 | $2.58M derived: sum of 3 quarters · filed 2026-03-09 | $3.15M 10-K · filed 2026-03-09 |
| 2024-09-30 | $683.00K 10-Q · filed 2025-11-10 | $1.31M derived: sum of 2 quarters · filed 2025-11-10 | $1.89M 10-Q · filed 2025-11-10 | $2.46M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $628.00K 10-Q · filed 2025-08-11 | $1.21M 10-Q · filed 2025-08-11 | $1.78M derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | $577.00K 10-Q · filed 2025-05-15 | $1.15M derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $1.62M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $1.04M 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |